Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma

The management of HCC differs depending on the extent of disease. Surgery may be offered in selected cases of T4 disease as defined by AJCC 8th. However, outcome data post partial hepatectomy (PH) for T4 disease is scarce. We sought to evaluate the outcomes of patients post resection of T4 HCC and a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgical oncology 2021-12, Vol.39, p.101671-101671, Article 101671
Hauptverfasser: Linn, Yun-Le, Chua, Darren W., Koh, Ye-Xin, Tan, Ek-Khoon, Teo, Jin-Yao, Cheow, Peng-Chung, Jeyaraj, Prema Raj, Chow, Pierce K.H., Ooi, London L.P.J., Chung, Alexander Y.F., Chan, Chung-Yip, Goh, Brian K.P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 101671
container_issue
container_start_page 101671
container_title Surgical oncology
container_volume 39
creator Linn, Yun-Le
Chua, Darren W.
Koh, Ye-Xin
Tan, Ek-Khoon
Teo, Jin-Yao
Cheow, Peng-Chung
Jeyaraj, Prema Raj
Chow, Pierce K.H.
Ooi, London L.P.J.
Chung, Alexander Y.F.
Chan, Chung-Yip
Goh, Brian K.P.
description The management of HCC differs depending on the extent of disease. Surgery may be offered in selected cases of T4 disease as defined by AJCC 8th. However, outcome data post partial hepatectomy (PH) for T4 disease is scarce. We sought to evaluate the outcomes of patients post resection of T4 HCC and assess preoperative predictive factors of early recurrence. We performed a retrospective review of 235 consecutive patients who underwent resection for T4 HCC from 2001 to 2018 at our institution. Median overall survival was 35.9 months (95% CI 25.7–46.0). 109 patients (49.5%) developed recurrence, of which 94 patients (42.7%) experienced early recurrence within 12 months. Median time to recurrence was 38.1 months. Multivariate analysis demonstrated that vascular invasion were significant independent preoperative predictor of early recurrence post resection. Patients who experienced early recurrence had a significantly shorter median overall survival 14.3 months (95% CI 25.7–46.0) compared to those who did not (55.5 months, 95% CI 40.6–70.8, p = .000). Selected patients with T4 HCC may benefit from PH. Macrovascular invasion was associated with early recurrence within 12 months. •Surgery may be offered in selected cases of T4 HCC, but outcome data is presently scarce.•We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months.•Macrovascular invasion was associated with early recurrence of T4 HCC post hepatectomy. Synopsis: Surgery may be offered in selected cases of T4 HCC, but the outcome data is presently scarce. We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months, with macrovascular invasion associated with early recurrence.
doi_str_mv 10.1016/j.suronc.2021.101671
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2597799485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740421001602</els_id><sourcerecordid>2597799485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-7309a23a3f34477e432551bcd4440c09dd5f2ec7658ffa489d2418f880d3c3b13</originalsourceid><addsrcrecordid>eNp9kE2L1EAQhhtR3HH1H4gEvHjJWP2RdPoiLMP6xcJ6WM9NT3cFe8ikY3WysP_ejlk9ePBUUDxv1cvD2GsOew68fX_a54XS6PcCBP-90vwJ2_FOm1pKAU_ZDkwLtVagLtiLnE8A0GrBn7MLqbRuhFQ7dvuNME1Ibo73WE2EIfo5Ua5SX6Gj4aEi9AsRjh7X3dXXw6G6U9UPnNycPA7DMjiqvCMfx3R2L9mz3g0ZXz3OS_b94_Xd4XN9c_vpy-HqpvbSwFxrCcYJ6WQvVemCSoqm4UcflFLgwYTQ9AK9bpuu753qTBCKd33XQZBeHrm8ZO-2uxOlnwvm2Z5jXuu4EdOSrWiM1saorino23_QU1poLO2saKE1xZLoCqU2ylPKmbC3E8WzowfLwa527cluwu0q3G7CS-zN4_HleMbwN_THcAE-bAAWG_cRyWYfV5shFrOzDSn-_8Mvv0-R1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2606909628</pqid></control><display><type>article</type><title>Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Linn, Yun-Le ; Chua, Darren W. ; Koh, Ye-Xin ; Tan, Ek-Khoon ; Teo, Jin-Yao ; Cheow, Peng-Chung ; Jeyaraj, Prema Raj ; Chow, Pierce K.H. ; Ooi, London L.P.J. ; Chung, Alexander Y.F. ; Chan, Chung-Yip ; Goh, Brian K.P.</creator><creatorcontrib>Linn, Yun-Le ; Chua, Darren W. ; Koh, Ye-Xin ; Tan, Ek-Khoon ; Teo, Jin-Yao ; Cheow, Peng-Chung ; Jeyaraj, Prema Raj ; Chow, Pierce K.H. ; Ooi, London L.P.J. ; Chung, Alexander Y.F. ; Chan, Chung-Yip ; Goh, Brian K.P.</creatorcontrib><description>The management of HCC differs depending on the extent of disease. Surgery may be offered in selected cases of T4 disease as defined by AJCC 8th. However, outcome data post partial hepatectomy (PH) for T4 disease is scarce. We sought to evaluate the outcomes of patients post resection of T4 HCC and assess preoperative predictive factors of early recurrence. We performed a retrospective review of 235 consecutive patients who underwent resection for T4 HCC from 2001 to 2018 at our institution. Median overall survival was 35.9 months (95% CI 25.7–46.0). 109 patients (49.5%) developed recurrence, of which 94 patients (42.7%) experienced early recurrence within 12 months. Median time to recurrence was 38.1 months. Multivariate analysis demonstrated that vascular invasion were significant independent preoperative predictor of early recurrence post resection. Patients who experienced early recurrence had a significantly shorter median overall survival 14.3 months (95% CI 25.7–46.0) compared to those who did not (55.5 months, 95% CI 40.6–70.8, p = .000). Selected patients with T4 HCC may benefit from PH. Macrovascular invasion was associated with early recurrence within 12 months. •Surgery may be offered in selected cases of T4 HCC, but outcome data is presently scarce.•We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months.•Macrovascular invasion was associated with early recurrence of T4 HCC post hepatectomy. Synopsis: Surgery may be offered in selected cases of T4 HCC, but the outcome data is presently scarce. We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months, with macrovascular invasion associated with early recurrence.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/j.suronc.2021.101671</identifier><identifier>PMID: 34775234</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Aged ; AJCC ; Blood platelets ; Carcinoma, Hepatocellular - epidemiology ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Classification ; Early recurrence ; Female ; Hepatectomy ; Hepatitis ; Hepatocellular carcinoma ; Humans ; Length of stay ; Liver cancer ; Liver Neoplasms - epidemiology ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Lymphocytes ; Male ; Middle Aged ; Mortality ; Multivariate analysis ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Neutrophils ; Patients ; Postoperative Complications - epidemiology ; Preoperative Care ; Retrospective Studies ; Risk Factors ; Sepsis ; Singapore - epidemiology ; Survival ; Tumors</subject><ispartof>Surgical oncology, 2021-12, Vol.39, p.101671-101671, Article 101671</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-7309a23a3f34477e432551bcd4440c09dd5f2ec7658ffa489d2418f880d3c3b13</citedby><cites>FETCH-LOGICAL-c390t-7309a23a3f34477e432551bcd4440c09dd5f2ec7658ffa489d2418f880d3c3b13</cites><orcidid>0000-0002-5949-4741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.suronc.2021.101671$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34775234$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Linn, Yun-Le</creatorcontrib><creatorcontrib>Chua, Darren W.</creatorcontrib><creatorcontrib>Koh, Ye-Xin</creatorcontrib><creatorcontrib>Tan, Ek-Khoon</creatorcontrib><creatorcontrib>Teo, Jin-Yao</creatorcontrib><creatorcontrib>Cheow, Peng-Chung</creatorcontrib><creatorcontrib>Jeyaraj, Prema Raj</creatorcontrib><creatorcontrib>Chow, Pierce K.H.</creatorcontrib><creatorcontrib>Ooi, London L.P.J.</creatorcontrib><creatorcontrib>Chung, Alexander Y.F.</creatorcontrib><creatorcontrib>Chan, Chung-Yip</creatorcontrib><creatorcontrib>Goh, Brian K.P.</creatorcontrib><title>Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>The management of HCC differs depending on the extent of disease. Surgery may be offered in selected cases of T4 disease as defined by AJCC 8th. However, outcome data post partial hepatectomy (PH) for T4 disease is scarce. We sought to evaluate the outcomes of patients post resection of T4 HCC and assess preoperative predictive factors of early recurrence. We performed a retrospective review of 235 consecutive patients who underwent resection for T4 HCC from 2001 to 2018 at our institution. Median overall survival was 35.9 months (95% CI 25.7–46.0). 109 patients (49.5%) developed recurrence, of which 94 patients (42.7%) experienced early recurrence within 12 months. Median time to recurrence was 38.1 months. Multivariate analysis demonstrated that vascular invasion were significant independent preoperative predictor of early recurrence post resection. Patients who experienced early recurrence had a significantly shorter median overall survival 14.3 months (95% CI 25.7–46.0) compared to those who did not (55.5 months, 95% CI 40.6–70.8, p = .000). Selected patients with T4 HCC may benefit from PH. Macrovascular invasion was associated with early recurrence within 12 months. •Surgery may be offered in selected cases of T4 HCC, but outcome data is presently scarce.•We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months.•Macrovascular invasion was associated with early recurrence of T4 HCC post hepatectomy. Synopsis: Surgery may be offered in selected cases of T4 HCC, but the outcome data is presently scarce. We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months, with macrovascular invasion associated with early recurrence.</description><subject>Aged</subject><subject>AJCC</subject><subject>Blood platelets</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Classification</subject><subject>Early recurrence</subject><subject>Female</subject><subject>Hepatectomy</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Length of stay</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Postoperative Complications - epidemiology</subject><subject>Preoperative Care</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sepsis</subject><subject>Singapore - epidemiology</subject><subject>Survival</subject><subject>Tumors</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2L1EAQhhtR3HH1H4gEvHjJWP2RdPoiLMP6xcJ6WM9NT3cFe8ikY3WysP_ejlk9ePBUUDxv1cvD2GsOew68fX_a54XS6PcCBP-90vwJ2_FOm1pKAU_ZDkwLtVagLtiLnE8A0GrBn7MLqbRuhFQ7dvuNME1Ibo73WE2EIfo5Ua5SX6Gj4aEi9AsRjh7X3dXXw6G6U9UPnNycPA7DMjiqvCMfx3R2L9mz3g0ZXz3OS_b94_Xd4XN9c_vpy-HqpvbSwFxrCcYJ6WQvVemCSoqm4UcflFLgwYTQ9AK9bpuu753qTBCKd33XQZBeHrm8ZO-2uxOlnwvm2Z5jXuu4EdOSrWiM1saorino23_QU1poLO2saKE1xZLoCqU2ylPKmbC3E8WzowfLwa527cluwu0q3G7CS-zN4_HleMbwN_THcAE-bAAWG_cRyWYfV5shFrOzDSn-_8Mvv0-R1g</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Linn, Yun-Le</creator><creator>Chua, Darren W.</creator><creator>Koh, Ye-Xin</creator><creator>Tan, Ek-Khoon</creator><creator>Teo, Jin-Yao</creator><creator>Cheow, Peng-Chung</creator><creator>Jeyaraj, Prema Raj</creator><creator>Chow, Pierce K.H.</creator><creator>Ooi, London L.P.J.</creator><creator>Chung, Alexander Y.F.</creator><creator>Chan, Chung-Yip</creator><creator>Goh, Brian K.P.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5949-4741</orcidid></search><sort><creationdate>202112</creationdate><title>Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma</title><author>Linn, Yun-Le ; Chua, Darren W. ; Koh, Ye-Xin ; Tan, Ek-Khoon ; Teo, Jin-Yao ; Cheow, Peng-Chung ; Jeyaraj, Prema Raj ; Chow, Pierce K.H. ; Ooi, London L.P.J. ; Chung, Alexander Y.F. ; Chan, Chung-Yip ; Goh, Brian K.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-7309a23a3f34477e432551bcd4440c09dd5f2ec7658ffa489d2418f880d3c3b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>AJCC</topic><topic>Blood platelets</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Classification</topic><topic>Early recurrence</topic><topic>Female</topic><topic>Hepatectomy</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Length of stay</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Postoperative Complications - epidemiology</topic><topic>Preoperative Care</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sepsis</topic><topic>Singapore - epidemiology</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Linn, Yun-Le</creatorcontrib><creatorcontrib>Chua, Darren W.</creatorcontrib><creatorcontrib>Koh, Ye-Xin</creatorcontrib><creatorcontrib>Tan, Ek-Khoon</creatorcontrib><creatorcontrib>Teo, Jin-Yao</creatorcontrib><creatorcontrib>Cheow, Peng-Chung</creatorcontrib><creatorcontrib>Jeyaraj, Prema Raj</creatorcontrib><creatorcontrib>Chow, Pierce K.H.</creatorcontrib><creatorcontrib>Ooi, London L.P.J.</creatorcontrib><creatorcontrib>Chung, Alexander Y.F.</creatorcontrib><creatorcontrib>Chan, Chung-Yip</creatorcontrib><creatorcontrib>Goh, Brian K.P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Linn, Yun-Le</au><au>Chua, Darren W.</au><au>Koh, Ye-Xin</au><au>Tan, Ek-Khoon</au><au>Teo, Jin-Yao</au><au>Cheow, Peng-Chung</au><au>Jeyaraj, Prema Raj</au><au>Chow, Pierce K.H.</au><au>Ooi, London L.P.J.</au><au>Chung, Alexander Y.F.</au><au>Chan, Chung-Yip</au><au>Goh, Brian K.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>39</volume><spage>101671</spage><epage>101671</epage><pages>101671-101671</pages><artnum>101671</artnum><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>The management of HCC differs depending on the extent of disease. Surgery may be offered in selected cases of T4 disease as defined by AJCC 8th. However, outcome data post partial hepatectomy (PH) for T4 disease is scarce. We sought to evaluate the outcomes of patients post resection of T4 HCC and assess preoperative predictive factors of early recurrence. We performed a retrospective review of 235 consecutive patients who underwent resection for T4 HCC from 2001 to 2018 at our institution. Median overall survival was 35.9 months (95% CI 25.7–46.0). 109 patients (49.5%) developed recurrence, of which 94 patients (42.7%) experienced early recurrence within 12 months. Median time to recurrence was 38.1 months. Multivariate analysis demonstrated that vascular invasion were significant independent preoperative predictor of early recurrence post resection. Patients who experienced early recurrence had a significantly shorter median overall survival 14.3 months (95% CI 25.7–46.0) compared to those who did not (55.5 months, 95% CI 40.6–70.8, p = .000). Selected patients with T4 HCC may benefit from PH. Macrovascular invasion was associated with early recurrence within 12 months. •Surgery may be offered in selected cases of T4 HCC, but outcome data is presently scarce.•We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months.•Macrovascular invasion was associated with early recurrence of T4 HCC post hepatectomy. Synopsis: Surgery may be offered in selected cases of T4 HCC, but the outcome data is presently scarce. We reviewed 235 patients post hepatectomy for T4 HCC and found median overall survival to be 35.9 months, with macrovascular invasion associated with early recurrence.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34775234</pmid><doi>10.1016/j.suronc.2021.101671</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5949-4741</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0960-7404
ispartof Surgical oncology, 2021-12, Vol.39, p.101671-101671, Article 101671
issn 0960-7404
1879-3320
language eng
recordid cdi_proquest_miscellaneous_2597799485
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Aged
AJCC
Blood platelets
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Classification
Early recurrence
Female
Hepatectomy
Hepatitis
Hepatocellular carcinoma
Humans
Length of stay
Liver cancer
Liver Neoplasms - epidemiology
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Lymphocytes
Male
Middle Aged
Mortality
Multivariate analysis
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Neutrophils
Patients
Postoperative Complications - epidemiology
Preoperative Care
Retrospective Studies
Risk Factors
Sepsis
Singapore - epidemiology
Survival
Tumors
title Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T08%3A31%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20predictors%20of%20early%20recurrence%20of%20AJCC%20T4%20hepatocellular%20carcinoma&rft.jtitle=Surgical%20oncology&rft.au=Linn,%20Yun-Le&rft.date=2021-12&rft.volume=39&rft.spage=101671&rft.epage=101671&rft.pages=101671-101671&rft.artnum=101671&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/j.suronc.2021.101671&rft_dat=%3Cproquest_cross%3E2597799485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2606909628&rft_id=info:pmid/34775234&rft_els_id=S0960740421001602&rfr_iscdi=true